BIOMAT Database Logo BIOMAT Database Logo

Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens. 2015

Rosalind Parkes-Ratanshi, and David Katende, and Jonathan Levin, and Katie Wakeham, and Grosskurth Heiner, and Anatoli Kamali, and David G Lalloo
MRC/UVRI Uganda Research Unit on AIDS, Uganda Virus Research Institute (UVRI), Entebbe, Uganda Liverpool School of Tropical Medicine, Liverpool, United Kingdom Infectious Diseases Insitute, Kampala, Uganda rratanshi@idi.co.ug.

BACKGROUND Anemia is a common problem in HIV in sub-Saharan Africa. We describe the contribution of antiretroviral therapy (ART) regimen to the incidence of anemia and changes in hemoglobin (Hb) in HIV-infected patients in Uganda. METHODS This study was nested in a prevention of cryptococcal disease trial (CRYPTOPRO; ISCRTN7648152). Patients received 3 different backbones of nucleoside reverse transcriptase inhibitor in a nonrandomized manner. RESULTS Of the 852 patients (161 on zidovudine [ZDV], 628 on stavudine [d4T], and 63 on tenofovir [TDF]; all received lamuvidine), the risk of developing grade 4 anemia was higher (adjusted hazard ratio 2.7) for those receiving ZDV than those receiving d4T. Those receivingd4T had a higher average increase in Hb than those receiving ZDV (P = .024) or TDF (P = .014). CONCLUSIONS In this observational study, ZDV was associated with severe anemia compared to d4T or TDF; those receiving ZDV and TDF had smaller increases in Hb after ART initiation. We encourage publication of data on cohorts using TDF from Africa.

UI MeSH Term Description Entries
D008297 Male Males
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006454 Hemoglobins The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements. Eryhem,Ferrous Hemoglobin,Hemoglobin,Hemoglobin, Ferrous
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068698 Tenofovir An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone. (R)-9-(2-phosphonylmethoxypropyl)adenine,9-(2-Phosphonomethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer,9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098,9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer,9-PMPA (tenofovir),Tenofovir Disoproxil,Tenofovir Disoproxil Fumarate,Viread,Disoproxil Fumarate, Tenofovir,Disoproxil, Tenofovir,Fumarate, Tenofovir Disoproxil
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000740 Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. Anemias
D014454 Uganda A republic in eastern Africa, south of SUDAN and west of KENYA. Its capital is Kampala. Republic of Uganda
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

Rosalind Parkes-Ratanshi, and David Katende, and Jonathan Levin, and Katie Wakeham, and Grosskurth Heiner, and Anatoli Kamali, and David G Lalloo
Correlation between plasma glucose and hemoglobin A1c in HIV-infected individuals receiving zidovudine and non-zidovudine containing antiretroviral therapy regimens.
January 2020, HIV research & clinical practice,
Rosalind Parkes-Ratanshi, and David Katende, and Jonathan Levin, and Katie Wakeham, and Grosskurth Heiner, and Anatoli Kamali, and David G Lalloo
Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
May 2008, HIV medicine,
Rosalind Parkes-Ratanshi, and David Katende, and Jonathan Levin, and Katie Wakeham, and Grosskurth Heiner, and Anatoli Kamali, and David G Lalloo
Emergence of zidovudine resistance in HIV-infected patients receiving stavudine.
March 2000, Journal of acquired immune deficiency syndromes (1999),
Rosalind Parkes-Ratanshi, and David Katende, and Jonathan Levin, and Katie Wakeham, and Grosskurth Heiner, and Anatoli Kamali, and David G Lalloo
Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.
June 2012, Journal of neurovirology,
Rosalind Parkes-Ratanshi, and David Katende, and Jonathan Levin, and Katie Wakeham, and Grosskurth Heiner, and Anatoli Kamali, and David G Lalloo
Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study.
March 2008, Lancet (London, England),
Rosalind Parkes-Ratanshi, and David Katende, and Jonathan Levin, and Katie Wakeham, and Grosskurth Heiner, and Anatoli Kamali, and David G Lalloo
Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
August 2003, The Journal of infection,
Rosalind Parkes-Ratanshi, and David Katende, and Jonathan Levin, and Katie Wakeham, and Grosskurth Heiner, and Anatoli Kamali, and David G Lalloo
Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine.
October 2018, Journal of managed care & specialty pharmacy,
Rosalind Parkes-Ratanshi, and David Katende, and Jonathan Levin, and Katie Wakeham, and Grosskurth Heiner, and Anatoli Kamali, and David G Lalloo
Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
May 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Rosalind Parkes-Ratanshi, and David Katende, and Jonathan Levin, and Katie Wakeham, and Grosskurth Heiner, and Anatoli Kamali, and David G Lalloo
High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.
October 2012, Antiviral research,
Rosalind Parkes-Ratanshi, and David Katende, and Jonathan Levin, and Katie Wakeham, and Grosskurth Heiner, and Anatoli Kamali, and David G Lalloo
Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting.
May 2011, The Southeast Asian journal of tropical medicine and public health,
Copied contents to your clipboard!